Explore the Cellular Immunotherapy Program
Overview
The mission of the Mass General Cellular Immunotherapy Program is to invent, develop, administer, and understand engineered immune effector cells. Our approach is to expand cellular engineering and immunotherapy research by bringing together physicians and laboratory scientists focused on immune cell engineering and its clinical effects. We aim to enhance the cohesion between biological, translational, and clinical aspects of cell engineering to implement safe and potent immunotherapies, with the ultimate goal of developing curative treatments for cancer and other diseases.
Our objectives:
We aim to enhance the cohesion between biological, translational, and clinical aspects of cell engineering to implement safe and potent immunotherapies.
- Bring together clinical researchers who administer, manage, and/or investigate immune effector cells as a therapeutic modality
- Enable translational research and collaboration
- Optimize immune monitoring and laboratory correlatives of clinical observations
- Promote cellular therapy education through education sessions
- Provide high quality care and management of patients receiving cellular therapies
- Obtain and maintain FACT accreditation for the administration of immune effector cells
- Invent and develop novel forms of cellular engineering that will become the next generation of immune cell therapies
Clinical Trials
View Cellular Therapy clinical trials.
CAR T-Cell Therapies
Mass General Cancer Center is an authorized treatment center for FDA approved CAR T-cell therapies for adult patients with lymphoma (Breyanzi, Kymriah, Tecartus and Yescarta) and for adult patients with multiple myeloma (Abecma). Learn more.
TIL Therapy for Melanoma
Mass General Cancer Center is one of the first centers nationwide that offers FDA-approved Iovance TIL therapy (lifileucel) for patients with metastatic melanoma. Learn more.
CAR-T Therapy for Glioblastoma: INCIPIENT Clinical Trial
A research team from the Mass General Cancer Center recently conducted an early-stage trial of a new cell therapy for patients with recurrent glioblastoma. Preliminary results have shown remarkable initial responses among the first patients to receive the novel treatment. Learn more about the trial here and here.
If you are interested in learning more about the INCIPIENT clinical trial, please call 617-724-6226 or email carteamingbm@mgb.org. A member of our clinical team will contact you within 48 business hours.
-
Matthew Frigault, MD
- Clinical Director, Cellular Therapy Service
- John and Ashley Ranelli Endowed Scholar in Cancer Innovation
- Assistant Professor of Medicine, Harvard Medical School
-
Marcela Maus, MD, PhD
- Director, Cellular Immunotherapy Program
- Professor of Medicine, Harvard Medical School
A collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment.
Gene therapy offers durable treatments that modify defective genetic material to combat disease, while cell therapy involves the transplantation of healthy cells to repair or replace damaged tissue. Together, these therapies aim to restore proper cellular and genetic functions.
Noopur Raje, MD, Marcela Maus, MD, PhD and Matthew Frigault, MD discuss the power and evolution of immune therapies, specifically, CAR T-Cell therapy in treating cancer.
Of the many different approaches to activate the body’s immune system against cancer, CAR T-cell therapy is one of the most high tech and powerful treatments.
Marcela V. Maus, MD, PhD, Director of the Cellular Immunotherapy Program at the Mass General Cancer Center, was awarded a 2017 Stand Up to Cancer Innovative Research Grant for her work on "Potentiating Novel Engineered Cellular Therapies for Solid Tumors."
Kiss 108 FM’s Billy Costa talks with four experts from the Mass General Cancer Center to learn about what CAR T-cell therapy is and what impact it has on both patients and the medical community.
Kiss 108 FM’s Billy Costa gets a doctor’s perspective of CAR T-cell therapy with Mass General Cancer Center’s clinical director for the Center of Lymphoma, Dr. Jeremy Abramson.
Kiss 108 FM’s Billy Costa sits down with Dr. Marcela Maus, director of cellular immunotherapy at the Mass General Cancer Center, and discusses what CAR T-cell therapy is, who is eligible for treatments, and the future direction of CAR T-cell therapy.
Kiss 108 FM’s Billy Costa discusses CAR T-cell therapy with Mass General Cancer Center’s Dr. Matthew Frigault, medical oncologist and administrative director for Cellular Therapy Services, who explains how this therapy has the potential to impact patients in immense ways.
Watch how Mass General patient Jenn Gilmann has already benefited from immunotherapy.